Blogs

Call for BIA Board candidates. We are delighted to invite nominations from individuals interested in joining the BIA Board.

 In this blog, Abby Clark builds on a round table the BIA hosted with Chi Onwurah MP and Newcastle life science companies to explore the landscape and the drivers which make the sector strong, yet undervalued. 

In this blog, Martin Turner, Director of Policy and External Affairs at BIA, reflects on the long-anticipated Life Sciences Sector Plan and what it means for scaling UK biotech. This is the first in a series of blogs that will be released in the coming weeks.

In my final summer update as BIA CEO, I reflect on 12 amazing years and look ahead to my new role as Executive Chair of the Office for Life Sciences. This week we’ve also published our latest finance report, and we’re hiring - so if you’re looking for your next challenge, now’s the time to join Team BIA.

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager at BIA, shares insights from the BIA's first-of-its-kind funding and investment analysis into UK Deep Biotech.

In this blog, Paul Wann, Business Director Sustainability & Decarbonisation, Emerson, discusses how life sciences companies can reduce emissions and improve sustainability through advanced automation, process control, and efficient management of utilities without compromising the quality or availability of vital therapies.

In this blog, Dr Jonathan Tobin, Partner, Brandon Capital, explores how the UK pension industry can unlock greater economic and societal value by following Australia's example.

Alina O'Keeffe, Associate Director Marketing and Communications at BIA, attended BIA's recent Women in Biotech event in West London. It had one central finding: a more engaged Women in Biotech scene will engender a more dynamic sector for everyone.

MSD's record-breaking $10 billion acquisition of Verona Pharma illustrates the potential of our sector, but also is a reminder of the need to strengthen UK capital markets.

In this blog, James Buckley-Walker, Partner, 3PM, shares his vision of a smarter, more human-focused approach to lab design and operation.

In this article, Kate Barclay, Skills Strategy Consultant at BIA, outlines new changes to UK immigration law and how they will impact the life sciences sector. Prepared in collaboration with legal experts at Eversheds-Sutherland LLP.

In this blog, Albert Maguire-King, Media and Communications Executive at the BIA, shares the vision of hope witnessed at BIA's recent TechBio X event in Cambridge.

NHS 10 Year Health Plan for England, a strategy for European Life Sciences and hope to see you at the “sunny” BIA Summer Party on Wednesday.

In this blog, Sarah Potter, Partner - Patent Attorney and Robert Cogger-Ward, Associate at Potter Clarkson, share what you need to know about DSI and the Cali Fund.

OK, I admit defeat. The UK government has published 3.5 key strategies that affect our sector in a week and I’m expecting at least two more in the coming days – a full analysis of so much text by today is beyond me but…

In this latest white paper, Dave Cooper, Project Pursuit Manager at Emerson, explores how forward-thinking biotech companies can meet the growing demand for personalised treatments by reimagining their manufacturing strategies.

The Data (Use and Access) Act became law last week – but what does it mean for the life science sector? Fredericka Argent, Paul Maynard, and Tom Griffiths from Covington and Burling’s technology regulatory team explain all in this blog.

A major funding boost, support for scale-ups, and regulatory reform—this week’s update explores how the Government’s new Industrial Strategy backs our sector. Plus, Draig Therapeutics launches with $140 million, the UK shines at BIO in Boston, and Syncona sets its sights on future growth.

In this Q&A blog, BIA spoke to Natasha Gray, Associate & Life Sciences Advisory Service Lead at Warn, a new BIA member.

UK life sciences take centre stage at BIO following a promising Spending Review.